Published in Medical Imaging Business Week, January 5th, 2006
The first of these products is expected to be marketed in 2008. Aion has already started discussions with the U.S. Food and Drug Administration (FDA).
Aion has also moved its primary place of incorporation to the U.S, the world's largest healthcare and financial market, while creating a new Australian subsidiary. Aion Diagnostics, Inc., is a wholly owned subsidiary of global bionanotech company, pSivida Limited (PSDV, PSD, PSI) and owns the rights to commercialize diagnostics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.